Hydrosilylated porous silicon particles function as an intravitreal drug delivery system for daunorubicin

Journal of Ocular Pharmacology and Therapeutics

Volumn 29, Issue 5, 2013, Pages 493-500

  Hartmann, Kathrin I ^a   Nieto, Alejandra ^b   Wu, Elizabeth C ^c   Freeman, William R ^a   Kim, Jae Suk ^a   Chhablani, Jay ^a   Sailor, Michael J ^b,c   Cheng, Lingyun ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 UNDECENOIC ACID; DAUNORUBICIN; SILICON;

ANIMAL EXPERIMENT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; ELECTROSPRAY MASS SPECTROMETRY; HYDROSILYLATION; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; NONHUMAN; PARTICLE SIZE; SAFETY; SURFACE PROPERTY; VITREOUS BODY;

ANIMALS; CHROMATOGRAPHY, LIQUID; DAUNORUBICIN; DRUG DELIVERY SYSTEMS; INTRAVITREAL INJECTIONS; PARTICLE SIZE; POROSITY; RABBITS; SILICON; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TIME FACTORS; TOPOISOMERASE II INHIBITORS;

EID: 84878541965     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2012.0205     Document Type: Article

References (37)

1. Chappelow, A.V., and Kaiser, P.K. Neovascular age-related macular degeneration: potential therapies. Drugs. 68:1029-1036, 2008. (Pubitemid 351693673)
2. Martin, D.F., Maguire, M.G., Fine, S.L., et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 119:1388-1398, 2012.
3. Taban, M., Lowder, C.Y., and Kaiser, P.K. Outcome of flu-ocinolone acetonide implant (retisert(tm)) reimplantation for chronic noninfectious posterior uveitis. Retina. 28:1280-1288, 2008.
4. Lee, S.S., and Robinson, M.R. Novel drug delivery systems for retinal diseases. Ophthalmic Res. 41:124-135, 2009.
5. MacCumber, M.W., Sadeghi, S., Cohen, J.A., and Deutsch, T.A. Suture loop to aid in ganciclovir implant removal. Arch. Ophthalmol. 117:1250-1254, 1999. (Pubitemid 29428840)
6. Sieving, P.A., Caruso, R.C., Tao, W., et al. Ciliary neuro-trophic factor (cntf) for human retinal degeneration: phase i trial of cntf delivered by encapsulated cell intraocular implants. Proc. Natl. Acad. Sci. U. S. A. 103:3896-3901, 2006. (Pubitemid 43376652)
7. Short, B.G. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicol. Pathol. 36:49-62, 2008.
8. Bourges, J.L., Bloquel, C., Thomas, A., et al. Intraocular implants for extended drug delivery: therapeutic applications. Adv. Drug Deliv. Revi. 58:1182-1202, 2006. (Pubitemid 44794429)
9. Anglin, E.J., Cheng, L., Freeman, W.R., and Sailor, M.J. Porous silicon in drug delivery devices and materials. Adv. Drug Deliv. Rev. 60:1266-1277, 2008.
10. Hettiarachchi, K., and Lee, A.P. Polymer-lipid microbubbles for biosensing and the formation of porous structures. J. Colloid Interface Sci. 344:521-527, 2010.
11. Andrew, J.S., Anglin, E.J., Wu, E.C., et al. Sustained release of a monoclonal antibody from electrochemically prepared mesoporous silicon oxide. Adv. Funct. Mater. 20:4168-4174, 2010.
12. Cheng, L., Anglin, E., Cunin, F., et al. Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle. Br. J. Ophthalmol. 92:705-711, 2008. (Pubitemid 351684186)
13. Wu, E.C., Andrew, J.S., Cheng, L., et al. Real-time monitoring of sustained drug release using the optical properties of porous silicon photonic crystal particles. Biomaterials. 32: 1957-1966, 2011.
14. Low, S.P., Voelcker, N.H., Canham, L.T., and Williams, K.A. The biocompatibility of porous silicon in tissues of the eye. Biomaterials. 30:2873-2880, 2009.
15. Kashanian, S., Harding, F., Irani, Y., et al. Evaluation of mesoporous silicon/polycaprolactone composites as ophthalmic implants. Acta Biomaterialia. 6:3566-3572, 2010.
16. Retina Society Terminology Committee. The classification of retinal detachment with proliferative vitreoretinopathy. Ophtlamology. 90:121-125, 1983.
17. Sadaka, A., and Giuliari, G.P. Proliferative vitreoretino-pathy: current and emerging treatments. Clin. Ophthalmol. 6: 1325-1333, 2012.
18. Wickham, L., Bunce, C., Wong, D., McGurn, D., and Charteris, D.G. Randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology. 114:698-704, 2007. (Pubitemid 46483695)
19. Cheng, L.Y., Hostetler, K., Valiaeva, N., et al. Intravitreal crystalline drug delivery for intraocular proliferation diseases. Invest. Ophthalmol. Vis. Sci. 51:474-481, 2010.
20. Wiedemann, P., Hilgers, R.D., Bauer, P., and Heimann, K. Adjunctive daunorubicin in the treatment of proliferative vi-treoretinopathy: results of a multicenter clinical trial. Dauno-mycin study group. Am. J. Ophthalmol. 126:550-559, 1998. (Pubitemid 28475919)
21. Shinohara, K., Tanaka, M., Sakuma, T., and Kobayashi, Y. Efficacy of daunorubicin encapsulated in liposome for the treatment of proliferative vitreoretinopathy. Ophthalmic Surg. Lasers Imaging. 34:299-305, 2003. (Pubitemid 36869622)
22. Mietz, H., and Heimann, K. Onset and recurrence of pro-liferative vitreoretinopathy in various vitreoretinal disease. Br. J. Ophthalmol. 79:874-877, 1995.
23. Wiedemann, P., Kirmani, M., Santana, M., Sorgente, N., and Ryan, S.J. Control of experimental massive periretinal proliferation by daunomycin: dose-response relation. Graefes Arch. Clin. Exp. Ophthalmol. 220:233-235, 1983. (Pubitemid 13037305)
24. Khawly, J.A., Saloupis, P., Hatchell, D.L., and Machemer, R. Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 229:464-467, 1991.
25. Wiedemann, P., Sorgente, N., Bekhor, C., et al. Daunomycin in the treatment of experimental proliferative vitreoretino-pathy. Effective doses in vitro and in vivo. Invest. Ophthalmol. Vis. Sci. 26:719-725, 1985. (Pubitemid 15067813)
26. Wu, E.C., Andrew, J.S., Buyanin, A., Kinsella, J.M., and Sailor, M.J. Suitability of porous silicon microparticles for the long-term delivery of redox-active therapeutics. Chem. Commun. 47:5699-5701, 2011.
27. Maniez-Devos, D.M., Baurain, R., Lesne, M., and Trouet, A. Degradation of doxorubicin and daunorubicin in human and rabbit biological fluids. J. Pharm. Biomed. Anal. 4:353-365, 1986. (Pubitemid 16000098)
28. Houee-Levin, C., Benzineb, K., Gardes-Albert, M., Abe-dinzadeh, Z., and Ferradini, C. Reduction of daunorubicin in the presence of sulfur-containing peptides. Free Radic. Biol. Med. 11:573-580, 1991. (Pubitemid 121003263)
29. Marney, L.C., Laha, T.J., Baird, G.S., Rainey, P.M., and Hoofnagle, A.N. Isopropanol protein precipitation for the analysis of plasma free metanephrines by liquid chroma-tography-tandem mass spectrometry. Clin. Chem. 54:1729-1732, 2008.
30. Cheng, L., Hostetler, K.Y., Chaidhawangul, S., et al. In-travitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation. Invest. Ophthalmol. Vis. Sci. 41:1523-1532, 2000. (Pubitemid 30261879)
31. Brar, M., Cheng, L., Yuson, R., et al. Ocular safety profile and intraocular pharmacokinetics of an antagonist of ephb4/ephrinb2 signalling. Br. J. Ophthalmol. 94:1668-1673, 2010.
32. Cheng, L., Hostetler, K.Y., Chaidhawangul, S., et al. Treatment or prevention of herpes simplex virus retinitis with intravitreally injectable crystalline 1-o-hexadecylpropanediol-3-phospho-ganciclovir. Invest. Ophthalmol. Vis. Sci. 43:515-521, 2002. (Pubitemid 34113237)
33. Lehto, V.P., Vaha-Heikkila, K., Paski, J., and Salonen, J. Use of thermoanalytical methods in quantification of drug load in mesoporous silicon microparticles. J. Ther. Anal. Calorim. 80:393-397, 2005. (Pubitemid 40626513)
34. Salonen, J., Laitinen, L., Kaukonen, A.M., et al. Mesoporous silicon microparticles for oral drug delivery: Loading and re-leaseoffive model drugs.J.Controlled Release. 108:362-374, 2005. (Pubitemid 41608668)
35. Wu, E.C., Park, J-H., Park, J., et al. Oxidation-triggered release of fluorescent molecules or drugs from mesoporous si microparticles. ACS Nano. 2:2401-2409, 2008.
36. Anglin, E.J., Schwartz, M.P., Ng, V.P., Perelman, L.A., and Sailor, M.J. Engineering the chemistry and nanostructure of porous silicon fabry-pérot films for loading and release of a steroid. Langmuir. 20:11264-11269, 2004.
37. Canham, L.T., Reeves, C.L., Newey, J.P., et al. Derivatized mesoporous silicon with dramatically improved stability in simulated human blood plasma. Adv. Mater. 11:1505, 1999.